S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
ChatGPT Is Already "Old School" (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
ChatGPT Is Already "Old School" (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
ChatGPT Is Already "Old School" (Ad)
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
SunCar Technology Stock Overheats...Will it Rise Again?
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
ChatGPT Is Already "Old School" (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
ChatGPT Is Already "Old School" (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
ChatGPT Is Already "Old School" (Ad)
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
SunCar Technology Stock Overheats...Will it Rise Again?
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
ChatGPT Is Already "Old School" (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
ChatGPT Is Already "Old School" (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
ChatGPT Is Already "Old School" (Ad)
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
SunCar Technology Stock Overheats...Will it Rise Again?
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
ChatGPT Is Already "Old School" (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
ChatGPT Is Already "Old School" (Ad)
Here’s Why Disney’s MCU is Sinking in Quicksand
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
ChatGPT Is Already "Old School" (Ad)
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
SunCar Technology Stock Overheats...Will it Rise Again?
NASDAQ:CARA

Cara Therapeutics (CARA) Stock Forecast, Price & News

$3.16
+0.07 (+2.27%)
(As of 06/5/2023 ET)
Compare
Today's Range
$2.94
$3.31
50-Day Range
$3.09
$5.08
52-Week Range
$2.94
$12.98
Volume
1.49 million shs
Average Volume
853,807 shs
Market Capitalization
$170.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.83

Cara Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
401.1% Upside
$15.83 Price Target
Short Interest
Bearish
11.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.39
Upright™ Environmental Score
News Sentiment
0.69mentions of Cara Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$42,624 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

145th out of 985 stocks

Pharmaceutical Preparations Industry

61st out of 485 stocks


CARA stock logo

About Cara Therapeutics (NASDAQ:CARA) Stock

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Stock News Headlines

How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
Cara Therapeutics (NASDAQ: CARA)
How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
Q1 2023 Cara Therapeutics Inc Earnings Call
Cara Therapeutics (CARA) to Release Earnings on Monday
See More Headlines

CARA Price History

CARA Company Calendar

Last Earnings
11/07/2021
Today
6/06/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARA
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.83
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+401.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-85,470,000.00
Net Margins
-195.16%
Pretax Margin
-195.16%

Debt

Sales & Book Value

Annual Sales
$41.87 million
Book Value
$2.95 per share

Miscellaneous

Free Float
52,247,000
Market Cap
$170.55 million
Optionable
Optionable
Beta
0.87

Key Executives

  • Christopher A. PosnerChristopher A. Posner
    President, Chief Executive Officer & Director
  • Ryan D. Maynard
    Chief Financial Officer
  • Frèdèrique Menzaghi
    Chief Scientific Officer, Senior VP-R&D
  • Joana GoncalvesJoana Goncalves
    Chief Medical Officer
  • Scott M. TerrillionScott M. Terrillion
    Secretary & Chief Compliance Officer













CARA Stock - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CARA shares.
View CARA analyst ratings
or view top-rated stocks.

What is Cara Therapeutics' stock price forecast for 2023?

6 equities research analysts have issued twelve-month target prices for Cara Therapeutics' stock. Their CARA share price forecasts range from $4.00 to $25.00. On average, they anticipate the company's share price to reach $15.83 in the next year. This suggests a possible upside of 401.1% from the stock's current price.
View analysts price targets for CARA
or view top-rated stocks among Wall Street analysts.

How have CARA shares performed in 2023?

Cara Therapeutics' stock was trading at $10.74 at the start of the year. Since then, CARA shares have decreased by 70.6% and is now trading at $3.16.
View the best growth stocks for 2023 here
.

When is Cara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CARA earnings forecast
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.34. The biopharmaceutical company earned $20.27 million during the quarter, compared to analyst estimates of $15.74 million. Cara Therapeutics had a negative net margin of 195.16% and a negative trailing twelve-month return on equity of 49.31%. During the same period last year, the business posted ($0.35) EPS.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.09%), Bain Capital Life Sciences Investors LLC (4.08%), Farallon Capital Management LLC (3.70%), State Street Corp (3.53%), Kingdon Capital Management L.L.C. (2.28%) and Dimensional Fund Advisors LP (1.75%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends
.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $3.16.

How much money does Cara Therapeutics make?

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $170.55 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.

This page (NASDAQ:CARA) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -